Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Lasmiditan on the Heart in Healthy Participants
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT03465436
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Berlin, Germany
A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT03459612
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸Covance Clinical Research Inc, Madison, Wisconsin, United States
A Study of LY3074828 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Biological: LY3074828
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT03456713
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT03449433
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Biological: LebrikizumabDrug: Placebo
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 280
- Registration Number
- NCT03443024
- Locations
- 🇺🇸
Menter Dermatology Research, Dallas, Texas, United States
🇺🇸Integrated Clinical Research, LLC, West Palm Beach, Florida, United States
🇺🇸Arlington Research Center, Inc., Arlington, Texas, United States
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 440
- Registration Number
- NCT03435081
- Locations
- 🇺🇸
Care Access Research-Walnut Creek, Walnut Creek, California, United States
🇺🇸GWU/Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸Hamzavi Dermatology, Fort Gratiot, Michigan, United States
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 49
- Registration Number
- NCT03433677
- Locations
- 🇺🇸
Valley Research, Fresno, California, United States
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seville, Spain
🇺🇸Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 325
- Registration Number
- NCT03432286
- Locations
- 🇺🇸
Rehabilitation & Neurological Services, Huntsville, Alabama, United States
🇺🇸21st Century Neurology, a Division of Xenoscience, Inc., Phoenix, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 463
- Registration Number
- NCT03428100
- Locations
- 🇦🇹
KA Rudolfstiftung, Wien, Austria
🇦🇹Universitätsklinik Innsbruck, Innsbruck, Tyrol, Austria
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT03421379
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
🇯🇵For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Tokyo, Japan